secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001213900-25-076085
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial reports FDA agreement on Phase 3 design for AD04; Q2 net loss $2.0M, cash $5.9M
--------------------------------------------------------------------------------

- Completed End of Phase 2 meeting with FDA; agreement on key Phase 3 protocol elements for AD04 in Alcohol Use Disorder.
- Cash and equivalents $5.9M as of June 30, 2025 (up from $2.4M at March 31); cash runway into Q2 2026.
- Public offering closed June 17, 2025 raised net proceeds ~$3.0M from 11.1M shares and warrants at $0.3251.
- Entered manufacturing agreements with Thermo Fisher Scientific and Cambrex for AD04 drug product and substance.
- Regained Nasdaq compliance on July 14, 2025 for minimum stockholders' equity of $2.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/0001213900-25-076085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/ea0252930-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-076085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer